Susquehanna Fundamental Investments’s XBiotech XBIT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,863	Closed	-$72K	–	898
2023 Q1	$72K	Hold	20,863	–	–	﹤0.01%	914
2022 Q4	$73.2K	Sell	20,863 -537	-3%	-$1.83K	﹤0.01%	1132
2022 Q3	$77K	Buy	+21,400	New	+$101K	﹤0.01%	1357

Other funds holding XBIT

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's XBIT Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of XBiotech (XBIT) in Q2 2023, closing a stake of 20,863 shares — an estimated $72K sold.

Susquehanna Fundamental Investments first reported a position in XBIT in Q3 2022 and held it in 3 quarters. The position peaked at $77K in Q3 2022. 39 funds tracked by Wall St. Rank hold XBIT as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining XBiotech position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 20,863 XBiotech shares in Q2 2023, an estimated $72K.
Susquehanna Fundamental Investments first reported a position in XBiotech in Q3 2022 and held it in 3 quarters.
Susquehanna Fundamental Investments's XBiotech position peaked at $77K in Q3 2022.
39 funds tracked by Wall St. Rank held XBiotech as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.